C4 Therapeutics Announces Appointment of Andrew Phillips, Ph.D. As President and Chief Executive Officer

WATERTOWN, Mass. – C4 Therapeutics (C4T) today announced that Andrew Phillips, Ph.D. has been appointed as President and Chief Executive Officer. Dr. Phillips has been leading C4T’s scientific efforts as Chief Scientific Officer since January 2016 and assumed corporate leadership responsibilities with his added appointment as President in September 2016. In conjunction with Dr. Phillips…

C4 Therapeutics Announces Publication in Nature Chemical Biology on Degradation Technologies Licensed from Dana-farber Cancer Institute

CAMBRIDGE, Mass. – C4 Therapeutics (C4T) today announced that an independent study featuring targeted protein degradation technologies licensed by the Company from Dana-Farber Cancer Institute were published in Nature Chemical Biology. The paper (DOI: 10.1038/s41589-018-0021-8) describes a system using a degradation tag (dTAG) for proteins that is broadly applicable to target validation for drug discovery….